The outlook for 2025 is uncertain, with potential trade policy changes and corporate tax discussions possibly affecting business confidence and growth. Despite some pharmaceutical stocks performing well in this volatile environment, the sector has generally underperformed, with average share prices down 3.1% over the last month. Viatris shares have decreased by 2.3% during the same period, with analysts setting an average price target of $11.14, compared to the current share price of $8.99.